Bli medlem
Bli medlem

Du är här


Swedish Orphan Biovitrum AB: Invitation - Presentation of Sobi's Q4 and FY 2016 results

On 16 February 2017, at 08:00 CET, Swedish Orphan Biovitrum AB (publ)
( (Sobi™) will publish its report for the fourth
quarter and full year 2016.

Financial analysts and media are invited to participate in a telephone
conference, which will include a presentation of the results, on the
same day at 13:00 CET. The event will be hosted by Sobi's CEO and
President, Geoffrey McDonough, and the presentation will be held in

The presentation can be followed live, or afterwards on
Slides used in the presentation will be made available on Sobi's
website prior to the telephone conference.

To participate in the telephone conference, please call:

UK: +44 203 008 9809

SE: +46 8 566 426 93

US: +1 855 831 5948

Live audience URL:

(The recording will be made available via the audience URL within
three hours after the live broadcast.)


About Sobi™
Sobi is an international specialty healthcare company dedicated to
rare diseases. Sobi's mission is to develop and deliver innovative
therapies and services to improve the lives of patients. The product
portfolio is primarily focused on Haemophilia, Inflammation and
Genetic diseases. Sobi also markets a portfolio of specialty and rare
disease products across Europe, the Middle East, North Africa and
Russia for partner companies. Sobi is a pioneer in biotechnology with
world-class capabilities in protein biochemistry and biologics
manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion
(USD 385 M) and about 700 employees. The share (STO: SOBI) is listed
on Nasdaq Stockholm. More information is available at

For more information please contact

Media relations Investor relations
Linda Holmström, Senior Jörgen Winroth, Vice
Communications Manager President, Head of Investor
+46 70 873 40 95 +1 347-224-0819, +1 212-579
-0506, +46 8 697 2135

Swedish Orphan Biovitrum AB
Postal address SE-112 76 Stockholm, Sweden
Phone: 46 8 697 20 00


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.